178 filings
Page 8 of 9
8-K
1ug6uvc
15 Sep 16
Regulation FD Disclosure
12:00am
8-K
b55a7ov2 b1q
12 Sep 16
Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting
12:00am
8-K
w4zjtijo
2 Sep 16
Regulation FD Disclosure
12:00am
8-K
avdtucjcelt1guk6jt6b
9 Aug 16
Entry into a Material Definitive Agreement
12:00am
8-K
jy3pmm 4h
28 Jul 16
Versartis Reports Second Quarter 2016 Financial Results
12:00am
8-K
5enlqroic
3 Jun 16
Entry into a Material Definitive Agreement
12:00am
8-K
49ck2
23 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
s2v22t4
29 Apr 16
Versartis Reports First Quarter 2016 Financial Results
12:00am
8-K
o04 1qihp
4 Apr 16
Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
12:00am
8-K
x631sr8x3l
1 Apr 16
Regulation FD Disclosure
12:00am
8-K
1mon 2bu3es
18 Feb 16
Versartis Reports Fourth Quarter and Full Year 2015 Financial Results
12:00am
8-K
o8xm03wzd 2y5ud7t
3 Feb 16
Departure of Directors or Certain Officers
12:00am
8-K
l4qlyb
2 Feb 16
Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children
12:00am
8-K
dntynz92c1 8y
29 Oct 15
Versartis Reports Third Quarter 2015 Financial Results
12:00am
8-K
r1u8g kun1thmuyanb6
1 Oct 15
Regulation FD Disclosure
12:00am
8-K
eig8zn6lco18z9b5esp0
18 Sep 15
Versartis Announces Confirmatory 18-Month Data from Ongoing Extension Study of Somavaratan in GHD Children
12:00am
8-K
onwn3q00p
15 Sep 15
Other Events
12:00am
8-K
eyl64u8a0iqty5
4 Aug 15
Versartis Reports Second Quarter 2015 Financial Results
12:00am
8-K
yd3awg887x2wov2wc1p
28 May 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
njjs5nmwo1h64
15 May 15
Departure of Directors or Certain Officers
12:00am